These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37371793)

  • 21. Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models.
    Tuyaa-Boustugue P; Jantzen I; Zhang H; Young SP; Broqua P; Tallandier M; Entchev E
    Mol Genet Metab Rep; 2023 Dec; 37():101011. PubMed ID: 38053941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of residual arylsulfatase B activity in feline mucopolysaccharidosis VI by thiol-induced subunit association.
    Vine DT; McGovern MM; Schuchman EH; Haskins ME; Desnick RJ
    J Clin Invest; 1982 Feb; 69(2):294-302. PubMed ID: 6799547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Untargeted LC-HRMS metabolomics reveals candidate biomarkers for mucopolysaccharidoses.
    Torres CL; Scalco FB; de Oliveira MLC; Peake RWA; Garrett R
    Clin Chim Acta; 2023 Feb; 541():117250. PubMed ID: 36764508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and treatment strategies in mucopolysaccharidosis VI.
    Vairo F; Federhen A; Baldo G; Riegel M; Burin M; Leistner-Segal S; Giugliani R
    Appl Clin Genet; 2015; 8():245-55. PubMed ID: 26586959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.
    Byers S; Rozaklis T; Brumfield LK; Ranieri E; Hopwood JJ
    Mol Genet Metab; 1998 Dec; 65(4):282-90. PubMed ID: 9889015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.
    Alliston T
    J Pediatr Rehabil Med; 2010; 3(2):129-38. PubMed ID: 20628554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updated Confirmatory Diagnosis for Mucopolysaccharidoses in Taiwanese Infants and the Application of Gene Variants.
    Chuang CK; Tu YR; Lee CL; Lo YT; Chang YH; Liu MY; Liu HY; Chen HJ; Kao SM; Wang LY; Ho HJ; Lin HY; Lin SP
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational analysis of
    Malekpour N; Vakili R; Hamzehloie T
    Iran J Basic Med Sci; 2018 Sep; 21(9):950-956. PubMed ID: 30524696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmatic dermatan sulfate and chondroitin sulfate determination in mucopolysaccharidoses.
    Volpi N; Maccari F; Galeotti F; Zampini L; Santoro L; Padella L; Galeazzi T; Gabrielli O; Coppa GV
    J Pharm Biomed Anal; 2013 Nov; 85():40-5. PubMed ID: 23872470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
    Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
    Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational analysis of 105 mucopolysaccharidosis type VI patients.
    Karageorgos L; Brooks DA; Pollard A; Melville EL; Hein LK; Clements PR; Ketteridge D; Swiedler SJ; Beck M; Giugliani R; Harmatz P; Wraith JE; Guffon N; Leão Teles E; Sá Miranda MC; Hopwood JJ
    Hum Mutat; 2007 Sep; 28(9):897-903. PubMed ID: 17458871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
    Minami K; Morimoto H; Morioka H; Imakiire A; Kinoshita M; Yamamoto R; Hirato T; Sonoda H
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expert recommendations for the laboratory diagnosis of MPS VI.
    Wood T; Bodamer OA; Burin MG; D'Almeida V; Fietz M; Giugliani R; Hawley SM; Hendriksz CJ; Hwu WL; Ketteridge D; Lukacs Z; Mendelsohn NJ; Miller N; Pasquali M; Schenone A; Schoonderwoerd K; Winchester B; Harmatz P
    Mol Genet Metab; 2012 May; 106(1):73-82. PubMed ID: 22405600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arylsulfatase K inactivation causes mucopolysaccharidosis due to deficient glucuronate desulfation of heparan and chondroitin sulfate.
    Trabszo C; Ramms B; Chopra P; Lüllmann-Rauch R; Stroobants S; Sproß J; Jeschke A; Schinke T; Boons GJ; Esko JD; Lübke T; Dierks T
    Biochem J; 2020 Sep; 477(17):3433-3451. PubMed ID: 32856704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Possible Role for Arylsulfatase G in Dermatan Sulfate Metabolism.
    Poterala-Hejmo A; Golda A; Pacholczyk M; Student S; Tylki-Szymańska A; Lalik A
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
    Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
    Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
    Maccari F; Rigon L; Mantovani V; Galeotti F; Salvalaio M; D'Avanzo F; Zanetti A; Capitani F; Gabrielli O; Tomanin R; Volpi N
    J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucopolysaccharidosis III: Molecular basis and treatment.
    Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
    Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in MPS I and MPS II Disease Manifestations.
    Hampe CS; Yund BD; Orchard PJ; Lund TC; Wesley J; McIvor RS
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.